← Evidence library

BIB_403

ctDNA/MRD in resected melanoma — NEW 2026 pooled meta-analysis quantifies the diagnostic-performance CEILING: high specificity (~94–96%) but LOW sensitivity (31% landmark, 45% longitudinal) even in ~97% high-risk (stage IIB–IV) disease. STRENGTHENS the brief's existing "decline ctDNA/Signatera at Stage IB" position (BIB273, STATE iter 15) with a hard, citable false-negative number: a NEGATIVE ctDNA result is falsely reassuring — and shedding at Stage IB 0.8 mm is far lower than in the pooled high-risk population, so sensitivity at IB is worse still. Patient-protective vs Signatera/Natera mark…

Evidence grade

A

Tier

1 (Cancer Treat Rev — peer-reviewed systematic review/meta-analysis; 21 studies,

Cited by tasks

5, 6, 17, 24, 24a

Identifiers

DOI:10.1016/j

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_403/findings.md (research corpus). This page is a short context summary — not individualised medical advice.